GENETWORx Obtains Certification to Perform Pharmacogenetic Testing in New York State

GLEN ALLEN, Va., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Richmond-area laboratory GENETWORx has obtained certification to perform its DNA Drug-Response genetic testing on samples collected from patients in the state of New York. The laboratory will begin performing its pharmacogenetic testing panel that includes assays for drug metabolizing enzymes and cardiac disease risk factors for physicians in New York State.

The GENETWORx DNA Drug-Response Panel examines a patient's genetic metabolizer type for several of the most important Cytochrome P450 (CYP) enzymes that activate many commonly prescribed drugs for cardiology, pain management and psychiatry. This certification completes GENETWORx's state and federal accreditations and allows the laboratory to market to physicians in New York State, one of the largest markets for pharmacogenetic testing in the United States.

Because New York State quality standards for laboratories are one of the highest in the nation, many laboratories do not have certification to process samples from physicians in the state. GENETWORx's certification demonstrates the laboratory's high standards for quality.

GENETWORx CEO William Miller explained, "The New York State certification demonstrates our commitment to provide the highest quality laboratory services, and gives us a competitive edge over laboratories that are not certified in New York State."

GENETWORx's Laboratory Director, Sarah Jacobs-Helber, PhD, HCLD (ABB) added, "The addition of New York State certification completes our state and federal licensure process and allows GENETWORx to provide services to patients in all states. We are proud of the team we have put together and look forward to providing our unique brand of services to the citizens of New York."


GENETWORx is a fully accredited laboratory based in Glen Allen, Virginia. Its mission is to deliver meaningful personalized medicine results to patients and provide health care professionals the necessary tools to leverage their knowledge and truly individualize treatment plans based on a patient's DNA. Its scientists utilize the latest technology in DNA sequencing to help physicians choose the right medications, at the right dose, and effectively lower overall healthcare expenditures while delivering the best health outcome for the patient. For more information, visit the GENETWORx website at

CONTACT: For more information contact: William Miller, CEO GENETWORx 4060 Innslake Drive Glen Allen, VA 23060 804-346-4363